血清TK1和sCD30水平与T细胞淋巴瘤患者临床特征的相关性  

Correlation between serum TK1 and sCD30 levels and clinical characteristics of the patients with T cell non⁃Hodgkin lymphoma

作　　者：王欣[1] 梁艳丽 李艳秋 Wang Xin;Liang Yanli;Li Yanqiu(Department of Hemotology,Suining People’s Hospital Affiliated to Chongqing Medical University,Chongqing 629000,China)

机构地区：[1]重庆医科大学附属遂宁市中心医院血液科,重庆629000

出　　处：《海军医学杂志》2022年第1期65-69,共5页Journal of Navy Medicine

基　　金：遂宁市中心医院院级科研项目(2019y28)。

摘　　要：目的观察T细胞非霍奇金淋巴瘤(T⁃NHL)患者血清胸苷激酶1(TK1)和可溶性CD30(sCD30)表达情况,分析血清TK1和sCD30表达与T⁃NHL患者临床特征的关系。方法收集分析遂宁市中心医院2016年9月至2019年10月收治的32例T⁃NHL患者临床资料,观察所有患者临床特征,检测并比较不同临床特征T⁃NHL患者血清TK1和sCD30水平,分析血清TK1和sCD30表达与T⁃NHL患者临床特征的关系。结果有淋巴结外浸润、全身症状、不同病理类型的T⁃NHL患者血清TK1和sCD30水平比较差异无统计学意义(P>0.05);Ⅲ/Ⅳ期T⁃NHL患者血清TK1和sCD30水平均高于Ⅰ/Ⅱ期患者(P<0.05);单项Logistic回归分析结果显示,血清TK1和sCD30过表达均可能是T⁃NHL患者临床分期的影响因素(OR>1,P<0.05);受试者工作曲线(ROC)显示,当血清TK1和sCD30的截断值分别为1.375 pmol/L、130.245 kU/L时,可获得T⁃NHL患者临床高分期风险最佳预测价值,曲线下面积(AUC)分别为0.872、0.888,有一定预测价值。结论T⁃NHL患者临床分期可能与血清TK1和sCD30过度表达有关。检测血清TK1和sCD30水平可用于早期疾病分期的评价,并对疾病合理治疗方案的拟定有一定积极意义。Objective To observe the expression levels of serum thymidine kinase 1(TK1)and soluble CD30(sCD30)in the patients with T cell non⁃Hodgkin lymphoma(T⁃NHL),and also to analyze the relationship between the expression levels of serum TK1 and sCD30 and the clinical characteristics of T⁃NHL patients.Methods The clinical data of 32 patients with T cell T⁃NHL treated in the Suining Central Hospital from September 2016 to October 2019 were collected and analyzed retrospectively,and clinical character⁃istics of all the patients were observed closely.The serum levels of TK1 and sCD30 of the T⁃NHL patients with different clinical char⁃acteristics were detected,and the relationship between serum TK1 and sCD30 expression levels and clinical characteristics of T⁃NHL patients was analyzed.Results There was no statistical significance when comparisons were made between serum TK1 and sCD30 levels in the T⁃NHL patients with extralymph node invasion,systemic symptoms,and different T⁃cell lymphoma types(P>0.05).The serum TK1 and sCD30 levels of theⅢ/Ⅵstage T⁃NHL patients were all higher than those of theⅠ/Ⅱstage T⁃NHL patients(P<0.05).Single Logistic regression analysis indicated that the overexpression of serum TK1 and sCD30 might be the influencing factors of the clinical stage of T⁃NHL patients(OR>1,P<0.05).The ROC curve showed when the cut⁃off values of the serum TK1 and sCD30 were respectively 1.375pmol/L and 130.245kU/L,best predictive value of high clinical stage risk in the T⁃NHL patients could be obtained.The AUC values of 0.872 and 0.888 were of certain predictive value.Conclusion The clinical staging of the T⁃NHL patients may be related to the overexpression of serum TK1 and sCD30.The detection of serum TK1 and sCD30 levels and evaluation of early disease stages might be of significance for the development of proper treatment schemes in treatment of the disease.

关 键 词：非霍奇金淋巴瘤 胸苷激酶1 可溶性CD30 相关性 

分 类 号：R733.1[医药卫生—肿瘤]